The price-to-earnings ratio for Halozyme Therapeutics Inc (NASDAQ: HALO) is 18.36x, which is above its average ratio. Moreover, the 36-month beta value for HALO is 1.25. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for HALO is 122.23M and currently, short sellers hold a 8.24% of that float. On April 03, 2025, HALO’s average trading volume was 1.40M shares.
HALO) stock’s latest price update
The stock of Halozyme Therapeutics Inc (NASDAQ: HALO) has increased by 1.86 when compared to last closing price of 61.87. Despite this, the company has experienced a -1.25% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-31 that A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025 SAN DIEGO, March 31, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of a new Opdivo® (nivolumab) subcutaneous formulation developed with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme (rHuPH20), across multiple previously approved adult solid tumors as monotherapy, monotherapy maintenance following completion of nivolumab plus Yervoy® (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. The CHMP opinion will now be reviewed by the European Commission, which has the authority to approve medicines in the European Union.
HALO’s Market Performance
Halozyme Therapeutics Inc (HALO) has experienced a -1.25% fall in stock performance for the past week, with a 8.39% rise in the past month, and a 31.32% rise in the past quarter. The volatility ratio for the week is 2.79%, and the volatility levels for the past 30 days are at 2.93% for HALO. The simple moving average for the last 20 days is 0.25% for HALO stock, with a simple moving average of 13.82% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Wells Fargo repeating the rating for HALO by listing it as a “Equal Weight.” The predicted price for HALO in the upcoming period, according to Wells Fargo is $62 based on the research report published on October 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $57, previously predicting the price at $52. The rating they have provided for HALO stocks is “Neutral” according to the report published on September 19th, 2024.
Piper Sandler gave a rating of “Neutral” to HALO, setting the target price at $51 in the report published on June 07th of the previous year.
HALO Trading at 5.82% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.52% of loss for the given period.
Volatility was left at 2.93%, however, over the last 30 days, the volatility rate increased by 2.79%, as shares surge +5.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.66% upper at present.
During the last 5 trading sessions, HALO fell by -1.25%, which changed the moving average for the period of 200-days by +27.01% in comparison to the 20-day moving average, which settled at $62.86. In addition, Halozyme Therapeutics Inc saw 31.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from Henderson Jeffrey William, who sale 503 shares at the price of $64.05 back on Apr 01 ’25. After this action, Henderson Jeffrey William now owns 33,108 shares of Halozyme Therapeutics Inc, valued at $32,217 using the latest closing price.
Henderson Jeffrey William, the Director of Halozyme Therapeutics Inc, sale 5,000 shares at $58.69 during a trade that took place back on Mar 03 ’25, which means that Henderson Jeffrey William is holding 33,611 shares at $293,458 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.54 for the present operating margin
- 0.81 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.44. The total capital return value is set at 0.29. Equity return is now at value 198.42, with 22.79 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.81 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 4.14. The interest coverage ratio of the stock is 30.48.
Currently, EBITDA for the company is 656.54 million with net debt to EBITDA at 2.15. When we switch over and look at the enterprise to sales, we see a ratio of 9.04. The receivables turnover for the company is 3.29for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.80.
Conclusion
To wrap up, the performance of Halozyme Therapeutics Inc (HALO) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
